SONOMIND™

Based in France, Sonomind specializes in ultrasound therapeutics, focusing on innovative treatments for depression through non-invasive neuromodulation technology. Sonomind, founded in 2024, is a company located in Paris, France, that focuses on developing ultrasound therapies for mental health treatment. In May 2026, SONOMIND™ raised EUR 20 million in series A funding co-led by Critical Path Ventures and Bpifrance Investissement. Sonomind specializes in innovative therapeutic solutions aimed at treating depression through a non-invasive approach utilizing ultrasound neuromodulation technology.

Their core product leverages over 25 years of research conducted at the Physmed laboratory, focusing on deep transcranial ultrasound stimulation to target specific brain regions associated with depression. This technology is designed to provide rapid relief from severe treatment-resistant depression, achieving significant symptom reduction as evidenced by clinical studies. The company’s offerings are directed towards healthcare providers, including hospitals and mental health clinics, primarily in Europe and North America. Sonomind aims to reach a wide patient demographic affected by depression, which, according to the World Health Organization, includes over 300 million individuals globally.

Revenue generation for Sonomind is structured around the provision of its advanced ultrasound neuromodulation services to healthcare institutions. Transactions typically occur through partnerships with hospitals and mental health clinics, where the company offers treatment plans based on its proprietary technology. Specific pricing details for these services are set according to patient needs and treatment duration, reflecting the ongoing utility of their flagship offerings. By establishing a network of clinical partners, Sonomind is positioned to facilitate continuous revenue flow through the treatment of patients suffering from severe depression.

The company will use the May 2026 funding to launch large-scale clinical trials and advance development of its non-invasive ultrasound treatment for resistant depression.